

Cabazitaxel CARD

PRELIMINARY SCORE


CURATIVE


NON-CURATIVE

OS


ADJUSTMENTS


Quality of life







Serious and disabling adverse effects





Other adjustments





Cabazitaxel CARD

SCORE

CURATIVE

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

3

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Genitourinary Cancers
Therapeutic Indication: In combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen
Experimental Arm: Cabazitaxel + Prednisone or prednisolone
Control Arm: Abiraterone or enzalutamide (alternative to previously used)



